<DOC>
	<DOCNO>NCT00627666</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy donor bone marrow stem cell transplant help stop growth cancer cell . Chemotherapy antithymocyte globulin stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine methotrexate transplant may stop happen . PURPOSE : This phase II trial study well give donor stem cell transplant together busulfan , fludarabine , antithymocyte globulin work treat patient hematological cancer .</brief_summary>
	<brief_title>Donor Stem Cell Transplant After Busulfan , Fludarabine , Antithymocyte Globulin Treating Patients With Hematological Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To investigate whether unrelated donor hematopoietic stem cell transplantation use nonmyeloablative conditioning regimen comprise busulfan , fludarabine phosphate , anti-thymocyte globulin reduce treatment-related mortality patient hematologic malignancy . - To investigate whether regimen sufficiently immunosuppressive enable engraftment HLA-matched unrelated hematopoietic stem cell . OUTLINE : This multicenter study . Prior receive condition chemotherapy regimen , patient acute leukemia , chronic myelogenous leukemia ( CML ) , high-risk myelodysplastic syndrome ( chronic myelomonocytic leukemia , atypical CML , refractory anemia excess blast ) receive one dose intrathecal ( IT ) methotrexate . These patient also receive leucovorin calcium IV orally 4 hour IT methotrexate every 6 hour total 8 dos . - Nonmyeloablative conditioning regimen : Patients receive fludarabine phosphate IV 30 minute day -7 -2 , busulfan IV 3 hour day -7 -6 , anti-thymocyte globulin IV 4 hour day -4 -2 . - Allogeneic bone marrow stem cell transplantation ( SCT ) : Patients undergo allogeneic bone marrow SCT day 0 . - Graft-versus-host-disease ( GVHD ) prophylaxis : Patients receive cyclosporine ( CSA ) IV 2-4 hour every 12 hour start day -1 continue day 180 ( CSA give orally every 12 hour oral medication tolerate ) methotrexate IV day 1 , 3 , 6 , 11 . Once blood count recover , patient acute leukemia CML blast crisis resume IT methotrexate every 2 week total 3 dos . Patients also receive leucovorin calcium IV orally 4 hour IT methotrexate every 6 hour total 8 dos . Patients follow least 10 year SCT .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Acute leukemia Chronic myelogenous leukemia Myelodysplastic syndrome Must unrelated donor available match HLAA B serology DRB1 molecular type PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Bilirubin &lt; 3.0 mg/dL Creatinine &lt; 2.0 mg/dL AST ALT &lt; 3 time upper limit normal Not pregnant nursing Ejection fraction â‰¥ 45 % MUGA scan ECHO No major illness organ failure No severe psychiatric disorder mental deficiency make compliance treatment unlikely informed consent impossible PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>acute lymphocytic leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>mast cell leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>meningeal chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>refractory anemia excess blast</keyword>
</DOC>